Expression Study of NDUFS1, NDUFV1, and NDUFV2 in Schizophrenia and Paranoid Personality Disorder
Abstract
Background: Schizophrenia (SCZ) is a major psychiatric disorder with unclear etiology and biological diagnosis. Paranoid personality disorder (PPD) is a type-A personality disorder characterized by paranoia and generalized mistrust. The etiology and molecular mechanisms of SCZ and PPD are not clarified. The present study aimed to examine the expression alteration of three major genes of mitochondrial complex I in the peripheral blood of patients with SCZ and PPD, and its correlations with clinical features of patients, especially the five major personality traits. Materials and Methods: This case-control study was performed on 735 SCZ, 742 PPD, and 750 non-psychiatric individuals. The mRNAs level of NDUFS1, NDUFV1, and NDUFV2 were assessed using quantitative real-time polymerase chain reaction, and their correlations with psychiatric symptoms were assessed by the positive and negative syndrome scale and the brief psychiatric rating scale tests, as well as personality traits that were evaluated by NEO Five-Factor Inventory. Results: Findings showed significant overexpression of NDUFS1, NDUFV1, and NDUFV2 in patients with SCZ (P=0.001, P=0.002, and P=0.004, respectively) and PPD (P=0.001, P=0.003, and P=0.006, respectively) compared with non-psychiatrists. In addition, these genes were associated with positive psychiatric symptoms and neuroticism in SCZ (P=0.008) and PPD (P=0.01). Conclusion: Overexpression genes that encode subunits of complex I play an important role in SCZ and PPD etiology and severity of symptoms. It may bring evidence about the significant role of bioenergetics dysfunction in psychotic behaviors in different psychiatric situations.References
Ben-Shachar D, Karry R. Sp1 expression is disrupted in schizophrenia; a possible mechanism for the abnormal expression of mitochondrial complex I genes, NDUFV1 and NDUFV2. PLoS One. 2007;2(9):e817.
https://doi.org/10.1371/journal.pone.0000817
PMid:17786189 PMCid:PMC1950689
Mehler-Wex C, Duvigneau JC, Hartl RT, Ben-Shachar D, Warnke A, Gerlach M. Increased mRNA levels of the mitochondrial complex I 75-kDa subunit. Eur Child Adolesc Psychiatry. 2006;15(8):504-7.
https://doi.org/10.1007/s00787-006-0560-5
PMid:16788776
Karry R, Klein E, Shachar DB. Mitochondrial complex I subunits expression is altered in schizophrenia: a post-mortem study. Biol Psychiatry. 2004;55(7):676-84.
https://doi.org/10.1016/j.biopsych.2003.12.012
PMid:15038995
Falk A, Heine VM, Harwood AJ, Sullivan PF, Peitz M, Brüstle O, et al. Modeling psychiatric disorders: from genomic findings to cellular phenotypes. Mol Psychiatry. 2016;21(9):1167-79.
https://doi.org/10.1038/mp.2016.89
https://doi.org/10.1038/mp.2016.100
Birnbaum R, Weinberger DR. Genetic insights into the neurodevelopmental origins of schizophrenia. Nat Rev Neurosci. 2017;18(12):727-40.
https://doi.org/10.1038/nrn.2017.125
PMid:29070826
Dror N, Klein E, Karry R, Sheinkman A, Kirsh Z, Mazor M, et al. State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia. Mol Psychiatry. 2002;7(9):995-1001.
https://doi.org/10.1038/sj.mp.4001116
PMid:12399953
Black DW, Zimmerman M. Personality disorders. In: Young Adult Mental Health. USA: Oxfort University Press; 2010. p. 424.
https://doi.org/10.1093/med:psych/9780195332711.003.0026
Harper RG. Paranoid personality disorder. In: The Corsini encyclopedia of psychology. Wiley Online Library; 2010. p. 1-3.
https://doi.org/10.1002/9780470479216.corpsy0637
Akarsu S, Torun D, Bolu A, Erdem M, Kozan S, Ak M, Akar H, Uzun Ö. Mitochondrial complex I and III gene mRNA levels in schizophrenia, and their relationship with clinical features. J Mol Psychiatry. 2014;2(1):1-6.
https://doi.org/10.1186/s40303-014-0006-9
PMid:25713723 PMCid:PMC4307627
Kupfer DJ, First MB, Regier DA, editors. A research agenda for DSM V. American Psychiatric Pub; 2008.
Park C, Park SK. Molecular links between mitochondrial dysfunctions and schizophrenia. Mol Cells. 2012;33(2):105-10.
https://doi.org/10.1007/s10059-012-2284-3
PMid:22358509 PMCid:PMC3887718
Whitehurst T, Howes O. The role of mitochondria in the pathophysiology of schizophrenia: A critical review of the evidence focusing on mitochondrial complex one. Neurosci Biobehav Rev. 2022;132:449-64.
https://doi.org/10.1016/j.neubiorev.2021.11.047
PMid:34864002
Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992;59(5):1609-23.
https://doi.org/10.1111/j.1471-4159.1992.tb10990.x
PMid:1402908
Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry. 2013;74(6):400-9.
https://doi.org/10.1016/j.biopsych.2013.03.018
PMid:23683390 PMCid:PMC4018767
Azadmarzabadi E, Haghighatfard A, Mohammadi A. Low resilience to stress is associated with candidate gene expression alterations in the dopaminergic signalling pathway. Psychogeriatrics. 2018;18(3):190-201.
https://doi.org/10.1111/psyg.12312
PMid:29423959
Abbasy S, Shahraki F, Haghighatfard A, Qazvini MG, Rafiei ST, et al. Neuregulin1 types mRNA level changes in autism spectrum disorder, and is associated with deficit in executive functions. EBioMedicine. 2018;37:483-8.
https://doi.org/10.1016/j.ebiom.2018.10.022
PMid:30415889 PMCid:PMC6284419
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005;79(2-3):231-8.
https://doi.org/10.1016/j.schres.2005.04.008
PMid:15982856
Ventura J, Nuechterlein KH, Subotnik KL, Gutkind D, Gilbert EA. Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatry Res. 2000;97(2-3):129-35.
https://doi.org/10.1016/S0165-1781(00)00228-6
PMid:11166085
Haghighatfard A, Andalib S, Amini Faskhodi M, Sadeghi S, Ghaderi AH, Moradkhani S, et al. Gene expression study of mitochondrial complex I in schizophrenia and paranoid personality disorder. World J Biol Psychiatry. 2018;19(sup3):S133-46.
https://doi.org/10.1080/15622975.2017.1282171
PMid:28635542
Roshan Chesly R, Shaeeri MR, Atrifard M, Nikkhah A, Ghaem Maghami B, Rahimierad A. Investigating psychometric properties of â NEO-five factor inventoryâ (NEO-FFI). Clinical Psychology and Personality. 2006;4(1):27-36.
Gonzalez-Liencres C, Tas C, Brown EC, Erdin S, Onur E, Cubukcoglu Z, et al. Oxidative stress in schizophrenia: a case-control study on the effects on social cognition and neurocognition. BMC Psychiatry. 2014;14(1):1-9.
https://doi.org/10.1186/s12888-014-0268-x
PMid:25248376 PMCid:PMC4180831
Ben-Shachar D, Zuk R, Gazawi H, Reshef A, Sheinkman A, Klein E. Increased mitochondrial complex I activity in platelets of schizophrenic patients. Int J Neuropsychopharmacol. 1999;2(4):245-53.
https://doi.org/10.1017/S1461145799001649
PMid:11285140
Taurines R, Thome J, Duvigneau JC, Forbes-Robertson S, Yang L, Klampfl K, et al. Expression analyses of the mitochondrial complex I 75-kDa subunit in early onset schizophrenia and autism spectrum disorder: increased levels as a potential biomarker for early onset schizophrenia. Eur Child Adolesc Psychiatry. 2010;19(5):441-8.
https://doi.org/10.1007/s00787-009-0074-z
PMid:19894076
Washizuka S, Kametani M, Sasaki T, Tochigi M, Umekage T, Kohda K, et al. Association of mitochondrial complex I subunit gene NDUFV2 at 18p11 with schizophrenia in the Japanese population. Am J Med Genet B Neuropsychiatr Genet. 2006;141(3):301-4.
https://doi.org/10.1002/ajmg.b.30285
PMid:16508936
Ni P, Chung S. Mitochondrial dysfunction in schizophrenia. BioEssays. 2020;42(6):1900202.
https://doi.org/10.1002/bies.201900202
PMid:32338416
Bergman O, Karry R, Milhem J, Ben-Shachar D. NDUFV2 pseudogene (NDUFV2P1) contributes to mitochondrial complex I deficits in schizophrenia. Mol Psychiatry. 2020;25(4):805-20.
https://doi.org/10.1038/s41380-018-0309-9
PMid:30531937
Shi J, Yao Y, Zhan C, Mao Z, Yin F, Zhao X. The relationship between big five personality traits and psychotic experience in a large non-clinical youth sample: the mediating role of emotion regulation. Front Psychiatry. 2018;9:648.
https://doi.org/10.3389/fpsyt.2018.00648
PMid:30564151 PMCid:PMC6288374

Copyright (c) 2022 Galen Medical Journal

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).